The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×7•Originally published 29 April 2026•Updated 1 May 2026•

1 min read

Slim Family Increases ProKidney Stake to 36% via Major Share Conversion

Key Facts

1Vanguard Group disclosed ownership of 2,168,085 shares in MarketAxess Holdings Inc, representing a 6.09% stake.

The Slim family has increased its strategic stake in ProKidney Corp to 36% by holding over 73 million Class A shares, following a massive conversion to solidify voting power. In a new institutional development, Cormorant Asset Management disclosed a significant 9.71% passive stake in Bright Minds Biosciences Inc, holding 950,000 common shares through its Global Healthcare Master Fund. Parallel to this, Vanguard Group revealed new positions exceeding 5% in both Victoria's Secret & Co and Synaptics Inc, signaling robust interest in the retail and semiconductor sectors. Adding to the wave of shifts, a new filing was recorded for Arrowhead Pharmaceuticals, indicating fresh ownership movements. These activities, alongside recent positions in Veralto and Vertex Pharmaceuticals, underscore a broader trend of portfolio diversification by global asset managers. Analysts view the Slim family's consolidation and Cormorant's entry into biotech as strategic moves to secure long-term growth opportunities.

about 1 month ago

Version History

2 additional sources confirmed this story

Version 7about 1 month ago

What changed: Added details regarding Cormorant Asset Management's new 9.71% stake in Bright Minds Biosciences Inc.

Version 6about 1 month ago

What changed: Added information regarding a new Schedule 13G ownership filing for Arrowhead Pharmaceuticals to the existing narrative of major stakeholder shifts.

Version 5about 1 month ago

What changed: The story was updated to include Vanguard Group's disclosure of a new 5.20% passive stake in Victoria's Secret & Co.

Version 4about 1 month ago

What changed: Updated the story to include Vanguard's new disclosure of a 5.10% stake in Synaptics Inc.

Version 3about 1 month ago

What changed: Shifted focus from general Vanguard disclosures to the Slim family's specific stake increase in ProKidney via share conversion.

Version 2about 1 month ago

What changed: The story was updated to include new ownership disclosures by Vanguard Group in Veralto Corp and Vertex Pharmaceuticals, adding to the previously reported stake in Pool Corp.

Version 1about 1 month ago

What changed: Updated the story to reflect a new regulatory filing by Vanguard Group regarding an ownership stake in Pool Corp, replacing the previous disclosure for MarketAxess.